FMRpolyG accumulates in FMR1 premutation granulosa cells.
COV434
FMR1 premutation carriers
FMRpolyG
FXPOI
RAN translation
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
26 Feb 2020
26 Feb 2020
Historique:
received:
26
11
2019
accepted:
10
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
28
10
2020
Statut:
epublish
Résumé
Fragile X premutation (Amplification of CGG number 55-200) is associated with increased risk for fragile X-Associated Premature Ovarian Insufficiency (FXPOI) in females and fragile X-associated tremor/ataxia syndrome (FXTAS) predominantly in males. Recently, it has been shown that CGG repeats trigger repeat associated non-AUG initiated translation (RAN) of a cryptic polyglycine-containing protein, FMRpolyG. This protein accumulates in ubiquitin-positive inclusions in neuronal brain cells of FXTAS patients and may lead to protein-mediated neurodegeneration. FMRpolyG inclusions were also found in ovary stromal cells of a FXPOI patient. The role of FMRpolyG expression has not been thoroughly examined in folliculogenesis related cells. The main goal of this study is to evaluate whether FMRpolyG accumulates in mural granulosa cells of FMR1 premutation carriers. Following FMRpolyG detection, we aim to examine premutation transfected COV434 as a suitable model used to identify RAN translation functions in FXPOI pathogenesis. FMRpolyG and ubiquitin immunostained mural granulosa cells from six FMR1 premutation carriers demonstrated FMRpolyG aggregates. However, co-localization of FMRpolyG and ubiquitin appeared to vary within the FMR1 premutation carriers' group as three exhibited partial ubiquitin and FMRpolyG double staining and three premutation carriers demonstrated FMRpolyG single staining. None of the granulosa cells from the five control women expressed FMRpolyG. Additionally, human ovarian granulosa tumor, COV434, were transfected with two plasmids; both expressing 99CGG repeats but only one enables FMRpolyG expression. Like in granulosa cells from FMR1 premutation carriers, FMRpolyG aggregates were found only in COV434 transfected with expended CGG repeats and the ability to express FMRpolyG. Corresponding with previous studies in FXTAS, we demonstrated accumulation of FMRpolyG in mural granulosa cells of FMR1 premutation carriers. We also suggest that following further investigation, the premutation transfected COV434 might be an appropriate model for RAN translation studies. Detecting FMRpolyG accumulation in folliculogenesis related cells supports previous observations and imply a possible common protein-mediated toxic mechanism for both FXPOI and FXTAS.
Sections du résumé
BACKGROUND
BACKGROUND
Fragile X premutation (Amplification of CGG number 55-200) is associated with increased risk for fragile X-Associated Premature Ovarian Insufficiency (FXPOI) in females and fragile X-associated tremor/ataxia syndrome (FXTAS) predominantly in males. Recently, it has been shown that CGG repeats trigger repeat associated non-AUG initiated translation (RAN) of a cryptic polyglycine-containing protein, FMRpolyG. This protein accumulates in ubiquitin-positive inclusions in neuronal brain cells of FXTAS patients and may lead to protein-mediated neurodegeneration. FMRpolyG inclusions were also found in ovary stromal cells of a FXPOI patient. The role of FMRpolyG expression has not been thoroughly examined in folliculogenesis related cells. The main goal of this study is to evaluate whether FMRpolyG accumulates in mural granulosa cells of FMR1 premutation carriers. Following FMRpolyG detection, we aim to examine premutation transfected COV434 as a suitable model used to identify RAN translation functions in FXPOI pathogenesis.
RESULTS
RESULTS
FMRpolyG and ubiquitin immunostained mural granulosa cells from six FMR1 premutation carriers demonstrated FMRpolyG aggregates. However, co-localization of FMRpolyG and ubiquitin appeared to vary within the FMR1 premutation carriers' group as three exhibited partial ubiquitin and FMRpolyG double staining and three premutation carriers demonstrated FMRpolyG single staining. None of the granulosa cells from the five control women expressed FMRpolyG. Additionally, human ovarian granulosa tumor, COV434, were transfected with two plasmids; both expressing 99CGG repeats but only one enables FMRpolyG expression. Like in granulosa cells from FMR1 premutation carriers, FMRpolyG aggregates were found only in COV434 transfected with expended CGG repeats and the ability to express FMRpolyG.
CONCLUSIONS
CONCLUSIONS
Corresponding with previous studies in FXTAS, we demonstrated accumulation of FMRpolyG in mural granulosa cells of FMR1 premutation carriers. We also suggest that following further investigation, the premutation transfected COV434 might be an appropriate model for RAN translation studies. Detecting FMRpolyG accumulation in folliculogenesis related cells supports previous observations and imply a possible common protein-mediated toxic mechanism for both FXPOI and FXTAS.
Identifiants
pubmed: 32101156
doi: 10.1186/s13048-020-00623-w
pii: 10.1186/s13048-020-00623-w
pmc: PMC7045455
doi:
Substances chimiques
FMR1 protein, human
0
Fragile X Mental Retardation Protein
139135-51-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Subventions
Organisme : Azrieli Foundation
ID : Private Donation
Références
Hum Reprod. 2016 Jan;31(1):158-68
pubmed: 26537920
Hum Mol Genet. 2002 Apr 1;11(7):805-14
pubmed: 11929853
Hum Reprod. 1997 Feb;12(2):241-3
pubmed: 9070703
Hum Genet. 2004 Apr;114(5):439-47
pubmed: 14758538
Hum Reprod. 1998 May;13(5):1184-7
pubmed: 9647544
Neuron. 2017 Jan 18;93(2):331-347
pubmed: 28065649
Reprod Biomed Online. 2009 Sep;19(3):385-90
pubmed: 19778484
Neuron. 2013 May 8;78(3):440-55
pubmed: 23602499
Curr Opin Genet Dev. 2002 Jun;12(3):284-93
pubmed: 12076671
Neuron. 2007 Aug 16;55(4):565-71
pubmed: 17698010
Fertil Steril. 2009 Aug;92(2):464-70
pubmed: 18973899
Fertil Steril. 2007 Mar;87(3):456-65
pubmed: 17074338
Mov Disord. 2007 Oct 31;22(14):2018-30, quiz 2140
pubmed: 17618523
Reproduction. 2013 Apr 15;145(4):335-43
pubmed: 23401597
Acta Neuropathol. 2013 Jul;126(1):1-19
pubmed: 23793382
EMBO J. 2010 Apr 7;29(7):1248-61
pubmed: 20186122
Neuron. 2007 Aug 16;55(4):556-64
pubmed: 17698009
Nat Commun. 2017 Dec 8;8(1):2005
pubmed: 29222490
F1000Res. 2017 Nov 29;6:2069
pubmed: 29225794
Elife. 2014 Aug 21;3:e03528
pubmed: 25144939
J Clin Endocrinol Metab. 1988 Dec;67(6):1190-4
pubmed: 3142914
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):260-5
pubmed: 21173221
Reproduction. 2002 Nov;124(5):601-9
pubmed: 12416998
Neurology. 2001 Jul 10;57(1):127-30
pubmed: 11445641
Nature. 2012 Dec 20;492(7429):382-6
pubmed: 23235829
Eur J Hum Genet. 2000 Apr;8(4):247-52
pubmed: 10854106
Acta Neuropathol Commun. 2014 Nov 26;2:162
pubmed: 25471011
Am J Med Genet. 1999 Apr 2;83(4):322-5
pubmed: 10208170
Front Cell Neurosci. 2017 May 05;11:128
pubmed: 28529475
Hum Reprod. 1994 Feb;9(2):245-52
pubmed: 8027280
Neurol Clin. 2014 Aug;32(3):705-19, viii
pubmed: 25037086
J Neurodev Disord. 2014;6(1):23
pubmed: 25161746
Cancer Res. 1991 Dec 15;51(24):6677-85
pubmed: 1660345
PLoS One. 2014 Aug 25;9(8):e105121
pubmed: 25153074
Mol Cell. 2014 Oct 23;56(2):311-322
pubmed: 25263597